Phased differentiation of γδ T and T CD8 tumor-infiltrating lymphocytes revealed by single-cell transcriptomics of human cancers. (1st January 2021)

• Record Type: Journal Article
• Authors: Cerapio, Juan-Pablo; Perrier, Marion; Balança, Camille-Charlotte; Gravelle, Pauline; Pont, Fréderic; Devaud, Christel; Franchini, Don-Marc; Féliu, Virginie; Tosolini, Marie; Valle, Carine; Lopez, Fréderic; Quillet-Mary, Anne; Ysebaert, Loic; Martinez, Alejandra; Delord, Jean Pierre; Ayyoub, Maha; Laurent, Camille; Fournie, Jean-Jacques
• Is Part Of: Oncoimmunology. Volume 10:Number 1(2021)
• Publication Date: 2021-01-01
• Subjects: Gamma-delta lymphocyte -- scRNAseq -- differentiation; Tumors -- Immunological aspects -- Periodicals; Neoplasms -- therapy -- Periodicals; Immunotherapy -- Periodicals; 616.994
• DOI: 10.1080/2162402X.2021.1939518
• Languages: English
• ISSNs: 2162-402X

Abstract

ABSTRACT: γδ T lymphocytes diverge from conventional T CD8 lymphocytes for ontogeny, homing, and antigen specificity, but whether their differentiation in tumors also deviates was unknown. Using innovative analyses of our original and ~150 published single-cell RNA sequencing datasets validated by phenotyping of human tumors and murine models, here we present the first high-resolution view of human γδ T cell differentiation in cancer. While γδ T lymphocytes prominently encompass TCRVγ9 cells more differentiated than T CD8 in healthy donor's blood, a different scenario is unveiled in tumors. Solid tumors and lymphomas are infiltrated by a majority of TCRVγnon9 γδ T cells which are quantitatively correlated and remarkably aligned with T CD8 for differentiation, exhaustion, gene expression profile, and response to immune checkpoint therapy. This cancer-wide association is critical for developing cancer immunotherapies.